RECOMBINANT PROUROKINASE IN ACUTE ISCHEMIC STROKE WITHIN 4.5 HOURS OF STROKE ONSET TRIAL-2 (PROST-2): A PHASE 3, MULTI-CENTRE, OPEN-LABEL, BLINDED-ENDPOINT, RANDOMISED CONTROLLED, NON-INFERIORITY TRIAL

被引：0
|
作者：
Li, S. [1 ]
Gu, H. [1 ]
Feng, B. [1 ]
Wang, Y. [1 ]
机构：
[1] Beijing Tiantan Hosp, Beijing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF STROKE | 2024年 / 19卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O126 / #3
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [1] RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial
    Li, Shuya
    Gu, Hong-Qiu
    Feng, Baoyu
    Dong, Qiang
    Fan, Dongsheng
    Xu, Yun
    Zhu, Suiqiang
    Wang, Yongjun
    INTERNATIONAL JOURNAL OF STROKE, 2024, 19 (10) : 1182 - 1187
  • [2] Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4<middle dot>5 h after stroke onset (PROST-2): a phase 3, open-label non-inferiority, randomised controlled trial
    Li, Shuya
    Gu, Hong-Qiu
    Feng, Baoyu
    Li, Hao
    Wang, Xuechun
    Dong, Qiang
    Fan, Dongsheng
    Xu, Yun
    Zhu, Suiqiang
    Dai, Hongguo
    Wei, Yan
    Wang, Ziran
    Lu, Guozhi
    Ma, Yutong
    Li, Zixiao
    Wang, Yilong
    Meng, Xia
    Zhao, Xingquan
    Liu, Liping
    Wang, Yongjun
    LANCET NEUROLOGY, 2025, 24 (01): : 33 - 41
  • [3] Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial
    Li, Shuya
    Gu, Hong-Qiu
    Dai, Hongguo
    Lu, Guozhi
    Wang, Yongjun
    STROKE AND VASCULAR NEUROLOGY, 2024, 9 (05) : 568 - 573
  • [4] Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial
    Mitchell, Peter J.
    Yan, Bernard
    Churilov, Leonid
    Dowling, Richard J.
    Bush, Steven J.
    Bivard, Andrew
    Huo, Xiao Chuan
    Wang, Guoqing
    Zhang, Shi Yong
    Ton, Mai Duy
    Cordato, Dennis J.
    Kleinig, Timothy J.
    Ma, Henry
    Chandra, Ronil, V
    Brown, Helen
    Campbell, Bruce C., V
    Cheung, Andrew K.
    Steinfort, Brendan
    Scroop, Rebecca
    Redmond, Kendal
    Miteff, Ferdinand
    Liu, Yan
    Duc, Dang Phuc
    Rice, Hal
    Parsons, Mark W.
    Wu, Teddy Y.
    Nguyen, Huy-Thang
    Donnan, Geoffrey A.
    Miao, Zhong Rong
    Davis, Stephen M.
    LANCET, 2022, 400 (10346): : 116 - 125
  • [5] Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial
    Xiong, Yunyun
    Hao, Manjun
    Pan, Yuesong
    Duan, Chunmiao
    Feng, Xueyan
    Li, Hao
    Wu, Na
    Wang, Liyuan
    Meng, Xia
    Zhao, Xingquan
    Wang, Yongjun
    STROKE AND VASCULAR NEUROLOGY, 2024,
  • [6] SAFETY AND EFFICACY OF RETEPLASE VERSUS ALTEPLASE FOR ACUTE ISCHEMIC STROKE: A PHASE 2, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT CONTROLLED TRIAL
    Li, S.
    Wang, X.
    Jin, A.
    Wang, Y.
    Zhao, X.
    Li, Z.
    Liu, L.
    Meng, X.
    Wang, Y.
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 428 - 428
  • [7] Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial
    Song, Haiqing
    Wang, Yuan
    Ma, Qingfeng
    Feng, Wuwei
    Liu, Rui
    Lv, Xiaomei
    Huang, Lijuan
    Li, Yifan
    Yang, Yi
    Geng, Deqin
    Zhu, Jianguo
    Wei, Yan
    Chen, Huisheng
    Zhu, Runxiu
    Zhai, Qijin
    Guo, Jing
    Liu, Bo
    Zhao, Shigang
    Wang, Yuping
    JAMA NETWORK OPEN, 2023, 6 (07) : e2325415
  • [8] Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial
    Kvistad, Christopher Elnan
    Naess, Halvor
    Helleberg, Bernt H.
    Idicula, Titto
    Hagberg, Guri
    Nordby, Linn Marie
    Jenssen, Kristian N.
    Tobro, Hakon
    Rorholt, Dag M.
    Kaur, Kamaljit
    Eltoft, Agnethe
    Evensen, Kristin
    Haasz, Judit
    Singaravel, Guruparan
    Fromm, Annette
    Thomassen, Lars
    LANCET NEUROLOGY, 2022, 21 (06): : 511 - 519
  • [9] Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol
    Bivard, Andrew
    Garcia-Esperon, Carlos
    Churilov, Leonid
    Spratt, Neil
    Russell, Michelle
    Campbell, Bruce C., V
    Choi, Philip
    Kleinig, Timothy
    Ma, Henry
    Markus, Hugh
    Molina, Carlos
    Hsu, Chung
    Tsai, Chon-Haw
    Meretoja, Atte
    Strbian, Daniel
    Butcher, Kenneth
    Wu, Teddy
    Davis, Stephen
    Donnan, Geoffrey
    Levi, Christopher
    Parsons, Mark
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (06) : 751 - 756
  • [10] Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial
    Anderson, Craig S.
    Huang, Yining
    Lindley, Richard I.
    Chen, Xiaoying
    Arima, Hisatomi
    Chen, Guofang
    Li, Qiang
    Billot, Laurent
    Delcourt, Candice
    Bath, Philip M.
    Broderick, Joseph P.
    Demchuk, Andrew M.
    Donnan, Geoffrey A.
    Durham, Alice C.
    Lavados, Pablo M.
    Lee, Tsong-Hai
    Levi, Christopher
    Martins, Sheila O.
    Olavarria, Veronica V.
    Pandian, Jeyaraj D.
    Parsons, Mark W.
    Pontes-Neto, Octavio M.
    Ricci, Stefano
    Sato, Shoichiro
    Sharma, Vijay K.
    Silva, Federico
    Song, Lili
    Thang, Nguyen H.
    Wardlaw, Joanna M.
    Wang, Ji-Guang
    Wang, Xia
    Woodward, Mark
    Chalmers, John
    Robinson, Thompson G.
    LANCET, 2019, 393 (10174): : 877 - 888
12345